<DOC>
	<DOC>NCT00853242</DOC>
	<brief_summary>The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (RenvelaÂ®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.</brief_summary>
	<brief_title>Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Serum phosphate level greater than (&gt;) 5.5 milligram per deciliter (mg/dL) (1.78 millimole per liter [mmol/L]) after discontinuation of current phosphate binder therapy Men or women 18 years or older Have active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Phosphate Binder</keyword>
	<keyword>Phosphate</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>